Auransa has developed a proprietary AI platform that analyzes extensive human disease data to identify novel therapeutics tailored for specific patient populations. The platform addresses the challenge of understanding complex diseases by predicting molecular disease subtypes and potential treatment responses based on genomic insights.
Funding
Funding not disclosed
Founders
Product
Problem
Drug development for complex diseases is hampered by a limited understanding of disease heterogeneity and patient-specific responses, leading to high failure rates in clinical trials and delayed access to effective treatments. Traditional approaches often overlook the underlying molecular subtypes and individual variations that influence therapeutic outcomes.
Solution
Auransa has developed a biology-first AI platform that leverages extensive human disease data, including over 500,000 gene expression profiles, to identify novel therapeutics tailored for specific patient populations. The platform predicts molecular disease subtypes and potential treatment responses based on genomic insights, enabling the discovery of differentiated therapeutics. By integrating data science with biological discovery, Auransa aims to improve the standard of cancer care and address unmet needs in other complex diseases. The AI platform harnesses abundant and heterogeneous human disease data to discover novel therapies for the most responsive patients.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and clinical investigators focused on developing targeted therapies for complex diseases, particularly in oncology.
Features
- AI-driven analysis of extensive human disease data to identify novel therapeutic targets
- Prediction of molecular disease subtypes and potential treatment responses based on genomic insights
- Advanced studies in liver cancer and heart-safe chemotherapy
- Integration of data science with biological discovery for precision medicine
- Identification of therapies tailored for specific patient populations